JP2011505386A - 白血病性幹細胞の阻害方法 - Google Patents

白血病性幹細胞の阻害方法 Download PDF

Info

Publication number
JP2011505386A
JP2011505386A JP2010536288A JP2010536288A JP2011505386A JP 2011505386 A JP2011505386 A JP 2011505386A JP 2010536288 A JP2010536288 A JP 2010536288A JP 2010536288 A JP2010536288 A JP 2010536288A JP 2011505386 A JP2011505386 A JP 2011505386A
Authority
JP
Japan
Prior art keywords
cells
aml
region
antibody
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2010536288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505386A5 (https=
Inventor
ジョン エドガー ディック
リキング ジン
ジーノ ルイジ ヴァイロ
デイヴィット ポール ギアリング
サマンサ ジェーン バスフィールド
Original Assignee
シーエスエル、リミテッド
ユニヴァーシティ ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエスエル、リミテッド, ユニヴァーシティ ヘルス ネットワーク filed Critical シーエスエル、リミテッド
Publication of JP2011505386A publication Critical patent/JP2011505386A/ja
Publication of JP2011505386A5 publication Critical patent/JP2011505386A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010536288A 2007-12-06 2008-12-04 白血病性幹細胞の阻害方法 Abandoned JP2011505386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99681907P 2007-12-06 2007-12-06
PCT/AU2008/001797 WO2009070844A1 (en) 2007-12-06 2008-12-04 Method of inhibition of leukemic stem cells

Publications (2)

Publication Number Publication Date
JP2011505386A true JP2011505386A (ja) 2011-02-24
JP2011505386A5 JP2011505386A5 (https=) 2011-12-01

Family

ID=40717202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010536288A Abandoned JP2011505386A (ja) 2007-12-06 2008-12-04 白血病性幹細胞の阻害方法

Country Status (13)

Country Link
US (6) US20110052574A1 (https=)
EP (1) EP2231187A4 (https=)
JP (1) JP2011505386A (https=)
KR (1) KR20100094527A (https=)
CN (1) CN101896200A (https=)
AU (1) AU2008331436A1 (https=)
BR (1) BRPI0819887A2 (https=)
CA (1) CA2706337A1 (https=)
EA (1) EA201070687A1 (https=)
IL (1) IL205951A0 (https=)
MX (1) MX2010006213A (https=)
WO (1) WO2009070844A1 (https=)
ZA (1) ZA201003515B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524296A (ja) * 2015-06-12 2018-08-30 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１２３抗体及びその複合体

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
US8492119B2 (en) * 2009-04-27 2013-07-23 Kyowa Hakko Kirin Co., Ltd Antibody to human IL-3 receptor alpha chain
JP2013505968A (ja) * 2009-10-01 2013-02-21 シーエスエル、リミテッド フィラデルフィア染色体陽性白血病の治療方法
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
AU2011217728B2 (en) * 2010-02-17 2013-03-14 Csl Limited Compositions and methods for targeting type 1 interferon producing cells
AU2013200910B2 (en) * 2010-02-17 2015-06-11 Csl Limited Composition and methods for targeting type 1 interferon producing cells
CN102821815A (zh) * 2010-02-18 2012-12-12 Csl有限公司 慢性炎症状态的治疗
US8920803B2 (en) 2010-06-15 2014-12-30 Csl Limited Immunotherapeutic method involving CD123 (IL-3Rα) antibodies and immunostimulating complex
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
AU2012202125B2 (en) * 2010-08-17 2015-03-19 Csl Limited Humanized Anti-Interleukin 3 Receptor Alpha Chain Antibodies
AU2011253598B1 (en) * 2010-08-17 2012-01-19 Csl Limited Humanized anti-interleukin 3 receptor alpha chain antibodies
NZ702415A (en) * 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
US20160031996A1 (en) * 2013-03-14 2016-02-04 Csl Limited Anti il-3r alpha agents and uses thereof
CN103740639A (zh) * 2013-09-02 2014-04-23 北京大学人民医院 构建人源化Ph染色体阳性急性淋巴细胞白血病小鼠模型的方法
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
KR20160111672A (ko) * 2015-03-17 2016-09-27 한밭대학교 산학협력단 규칙적으로 배열된 미세 부호를 포함하는 인쇄물에 대한 구동 시스템，방법 및 그 제작 방법
EP3280442A4 (en) * 2015-04-08 2018-10-31 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd123
RU2751512C2 (ru) 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
US20180320136A1 (en) * 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
AU2017236431A1 (en) 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
JP2021512103A (ja) 2018-01-31 2021-05-13 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ）
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
CN112042597B (zh) * 2020-07-22 2022-04-29 南京普恩瑞生物科技有限公司 一种双人源化肿瘤异种移植模型的构建方法
CN111920802B (zh) * 2020-09-11 2024-01-23 华侨大学 穿心莲内酯在制备防治成人t细胞白血病药物的应用
MX2023007901A (es) 2020-12-31 2023-07-11 Sanofi Sa Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123.
IL317227A (en) 2022-05-27 2025-01-01 Sanofi Sa Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering
TW202434305A (zh) 2022-11-17 2024-09-01 德商溫瑟克斯製藥公司 於腫瘤微環境中可裂解之抗體-藥物結合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177078B1 (en) * 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
JP2004509835A (ja) * 2000-03-06 2004-04-02 ユニヴァーシティ　オブ　ケンタッキー　リサーチ　ファンデーション 血液癌前駆細胞を障害する方法およびその関連化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177078B1 (en) * 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
JP2004509835A (ja) * 2000-03-06 2004-04-02 ユニヴァーシティ　オブ　ケンタッキー　リサーチ　ファンデーション 血液癌前駆細胞を障害する方法およびその関連化合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013020558; メルクマニュアル　第１８版　日本語版 , 20070425, ｐ．１２２７-１２３０, 日経ＢＰ社 *
JPN6013030704; Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｉｃａｌ　Ｍｅｔｈｏｄｓ Ｖｏｌ．３０６，　Ｎｏ．１-２, 2005, ｐ．１５１-１６０ *
JPN6013030706; Ｂｉｏｔｈｅｒａｐｙ 第１７巻，第５号, 200309, ｐ．４１５-４２１ *
JPN6013030708; Ｔｒｅｎｄｓ　ｉｎ　Ｇｌｙｃｏｓｃｉｅｎｃｅ　ａｎｄ　Ｇｌｙｃｏｔｅｃｈｎｏｌｏｇｙ 第１８巻，第１００号, 200603, ｐ．１２９-１３６ *
JPN6013030710; Ｂｌｏｏｄ Ｖｏｌ．８７，　Ｎｏ．１, 19960101, ｐ．８３-９２ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524296A (ja) * 2015-06-12 2018-08-30 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１２３抗体及びその複合体
JP2021000130A (ja) * 2015-06-12 2021-01-07 シアトル ジェネティクス インコーポレーテッド Ｃｄ１２３抗体及びその複合体

Also Published As

Publication number Publication date
IL205951A0 (en) 2010-11-30
EP2231187A4 (en) 2013-02-20
EP2231187A1 (en) 2010-09-29
CA2706337A1 (en) 2009-06-11
US20110052574A1 (en) 2011-03-03
US20170029515A1 (en) 2017-02-02
US20130230510A1 (en) 2013-09-05
AU2008331436A1 (en) 2009-06-11
EA201070687A1 (ru) 2010-12-30
CN101896200A (zh) 2010-11-24
ZA201003515B (en) 2011-08-31
KR20100094527A (ko) 2010-08-26
WO2009070844A1 (en) 2009-06-11
MX2010006213A (es) 2010-09-07
US20200207861A1 (en) 2020-07-02
US20180079818A1 (en) 2018-03-22
US20150152185A1 (en) 2015-06-04
BRPI0819887A2 (pt) 2017-05-23

Similar Documents

Publication Publication Date Title
JP2011505386A (ja) 白血病性幹細胞の阻害方法
CN111836830B (zh) Cd70组合疗法
JP2021118719A (ja) Ｔｉｇｉｔ結合物質およびその使用法
KR20150076178A (ko) T 세포 인게이저로서 이중특이적 IgG 항체
JP2022538733A (ja) 新規抗ｃｄ２５抗体
JP2022533253A (ja) ｃ－ｋｉｔ及びＣＤ４７に対する免疫療法剤の同時投与レジメン
AU2011267837B2 (en) Immunotherapeutic method involving CD123 (IL-3Ralpha) antibodies and immunostimulating complex
US20220288118A1 (en) Depletion regimes for engineered t-cell or nk-cell therapy
US20240368288A1 (en) Bispecific anti-flt3/cd3 antibodies and methods of use
CN118284621A (zh) 抗flt3抗体、car、car t细胞和使用方法
US20240216432A1 (en) Anti-flt3 antibodies, cars, car t cells and methods of use
US20250171533A1 (en) Kir3dl3 inhibitors and immune cell activating agents
WO2022214681A1 (en) Methods for the treatment of anaplastic large cell lymphoma
HK40095839A (en) Cd70 combination therapy
HK40033769A (en) Cd70 combination therapy
HK40031662B (en) Cd70 combination therapy
HK40031662A (en) Cd70 combination therapy
OA16352A (en) CD33 binding agents.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111012

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20121217

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20130327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131120